Prasco To Market Authorized Generic of NeoProfen® (ibuprofen lysine) Injection
CINCINNATI, OH MAY 22, 2014/PRNewswire/ — Prasco Laboratories announced today it has entered into a distribution and supply agreement with Recordati Rare Diseases Inc., for the rights to distribute Ibuprofen Lysine Injection, the Authorized Generic (AG) version of NeoProfen® (ibuprofen lysine) Injection. This product is the latest to be added to the Authorized Generic pipeline offered by Prasco. Additional information regarding the NeoProfen® AG will be forthcoming.
“We are pleased to welcome Recordati Rare Diseases as Prasco’s newest Authorized Generic partner. Prasco is committed to expanding patient access to brand quality pharmaceutical products through our Authorized Generics line,” stated Prasco chief executive officer, Chris Arington.
About Prasco Laboratories
Prasco, the Authorized Generic Company, is a privately held healthcare company located in Mason, Ohio. As the acknowledged category leader, Prasco has more Authorized Generic partnerships than any other company. Established brand companies rely on Prasco to bring their brand products to the generic marketplace as Authorized Generics, which offers alternatives to consumers and pharmacists. For more information, visit prasco.com.
About Recordati Rare Diseases
Recordati Rare Diseases (RRD) Inc. began marketing products to treat rare diseases in 2013. RRD is a member of the Recordati Group, which consists of Recordati S.p.A. and Orphan Europe. The Recordati Group was established in 1926 and now has over 3,200 employees worldwide.
RRD’s mission is to partner with patients, health care providers, advocacy and industry to make products available to treat rare and severe diseases.